192756-07-3
Chemical Structure
VRT-18858
Synonym(s): RU-36384
- CAS No.: 192756-07-3
- Formula:C24H25N5O7
- Molecular Weight:495.48
IUPAC Name: (S)-3-((1S,9S)-9-(isoquinoline-1-carboxamido)-6,10-dioxooctahydro-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxamido)-4-oxobutanoic acid
InChIKey: CUVNEENHHCPUBW-SZMVWBNQSA-N
SMILES: O=C([C@@H](NC(C1=NC=CC2=C1C=CC=C2)=O)CC3)N([C@H](C(N[C@H](C=O)CC(O)=O)=O)CCC4)N4C3=O
Biological Activity: VRT-18858 (RU-36384), the active metabolite of Pralnacasan (HY-19676), is a potent interleukin-1β converting enzyme (ICE) inhibitor (Ki = 1.4 nM). VRT-18858 inhibits LPS (HY-D1056)-induced IL-1β release (IC50 = 0.42 µM) and S. aureus Cowan-induced IL-1β and IL-18 release (IC50=1.3 and 2.1 µM, respectively) in human peripheral blood mononuclear cells. VRT-18858 can be used for osteoarthritis research[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
VRT-18858 | VRT-18858 (RU-36384), the active metabolite of Pralnacasan (HY-19676), is a potent interleukin-1β converting enzyme (ICE) inhibitor (Ki = 1.4 nM). VRT-18858 inhibits LPS (HY-D1056)-induced IL-1β release (IC50 = 0.42 µM) and S. aureus Cowan-induced IL-1β and IL-18 release (IC50=1.3 and 2.1 µM, respectively) in human peripheral blood mononuclear cells. VRT-18858 can be used for osteoarthritis research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
